v3.26.1
Collaboration, License and Option Agreements - Abbvie (Details)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Feb. 01, 2025
USD ($)
shares
Jun. 30, 2026
USD ($)
Mar. 31, 2026
USD ($)
Mar. 31, 2025
USD ($)
Dec. 31, 2025
USD ($)
Feb. 28, 2025
USD ($)
Program
$ / shares
Agreements            
Revenue     $ 12,648 $ 2,930    
Revenue from Contract with Customer, Product and Service     Collaboration And License Member Collaboration And License Member    
Deferred revenue     $ 48,010   $ 60,658  
Deferred revenue, current portion     31,542   40,023  
AbbVie Stock Purchase Agreement            
Agreements            
Common stock issued and sold (in shares) | shares 310,559          
Purchase price (in dollars per share) | $ / shares           $ 32.2
Development milestone related payment         5,000  
Transaction price           $ 7,100
AbbVie            
Agreements            
Gross proceeds from issuance of private placement $ 10,000          
Collaboration and Stock Purchase Agreement | AbbVie            
Agreements            
Additional program initiation period 3 years          
Gross proceeds from issuance of private placement     10,000      
Development milestone related payment     5,000      
Upfront payment     57,000      
Upfront payment, cash     42,000      
Maximum additional contingent payments receivable     2,100,000      
Maximum additional contingent payments receivable, Fees     305,000      
Maximum additional contingent payments receivable, Milestones     1,800,000      
Fair market value of common stock issued (in dollars)           2,900
Premium of common stock issued (in dollars)           7,100
Transaction price           $ 42,000
Revenue     8,000 $ 700    
Deferred revenue     26,012   $ 34,007  
Collaboration and Stock Purchase Agreement | AbbVie | Scenario Forecast            
Agreements            
Additional development milestone achieved   $ 6,000        
Collaboration and Stock Purchase Agreement | AbbVie | Maximum            
Agreements            
Number of programs | Program           4
Number of additional programs | Program           2
Initial Option Program, Material right for counterparty's right to substitute initial target with backup target | AbbVie            
Agreements            
Transaction price           $ 500
Initial Option Program, Right to receive additional services | AbbVie            
Agreements            
Transaction price           1,100
Initial Option Program, Material right to receive an exclusive license | AbbVie            
Agreements            
Transaction price           8,200
Initial Option Program Performance Obligation | AbbVie            
Agreements            
Transaction price           6,900
Collaboration Program Performance Obligation | AbbVie            
Agreements            
Transaction price           32,400
Collaboration Agreement | AbbVie            
Agreements            
Transaction price           $ 49,100
Deferred revenue     26,000      
Deferred revenue, current portion     $ 16,100